Joint Research and Development Agreement with Nippon Soda for Veterinary Pharmaceuticals
Fukuoka, Japan – KAICO Ltd. (Head Office: Fukuoka City, Fukuoka Prefecture; CEO: Kenta Yamato; hereinafter “KAICO”) is pleased to announce that it has entered into a joint research and development agreement with Nippon Soda Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President: Eiji Aga; hereinafter “Nippon Soda”) in the field of animal health for specific diseases.
This agreement was established in recognition of KAICO’s proprietary silkworm–baculovirus expression system, which enables the efficient production of high‑difficulty recombinant proteins. Under the agreement, KAICO will leverage this platform to express and supply proteins relevant to target disease indications.
In the rapidly evolving animal healthcare arena, there is an increasing need for innovative solutions that meet diversified and sophisticated demands. Through this collaboration, KAICO and Nippon Soda will synergize their technological and research strengths to conduct step‑wise technical verification, laying the groundwork for future product development and commercialization.
About Nippon Soda
Nippon Soda is a comprehensive chemical manufacturer committed to “creating new value through the power of chemistry, and enhancing corporate value through societal contribution.” The company operates across sectors including agriculture, pharmaceuticals, eco‑chemicals, and ICT specialty chemicals. In the life sciences domain, Nippon Soda is advancing solutions in pharmaceutical intermediates, agricultural inputs, and human and animal health challenges.
About KAICO
Founded in April 2018 as a Kyushu University venture, KAICO operates under the corporate mission: “Changing the world with silkworms.” The company’s core technology involves using silkworms as bioreactors via a proprietary silkworm–baculovirus expression system to produce pharmaceuticals, diagnostics, and research reagents. In collaboration with pharmaceutical partners, KAICO is developing novel drug candidates. Additionally, KAICO has filed patents for an oral vaccine platform utilizing silkworm-derived protein antigens and is advancing development of oral vaccines for both human and veterinary applications.
Leveraging this agreement as a catalyst, KAICO remains committed to expanding strategic partnerships across human and animal healthcare and related fields, accelerating its journey toward impactful innovation.